Neuroendocrine differentiation in prostate cancer: Current and emerging therapy strategies
Introduction
Increasing knowledge of the pathophysiology of prostate cancer (PC) has recently led to the identification of novel mechanisms of androgen independence and progression which, in turn, have allowed for numerous drug discoveries with an increasing therapeutic armamentarium for PC, particularly in the advanced stages. However, despite much progress, some aspects of PC – remain largely unknown. In recent years, increasing attention has been focused upon neuroendocrine differentiation (NED), above all for castration resistant prostate cancer (CRPC) patients, in which the identification of NED might be helpful mainly for tailoring therapeutic strategies, increasing survival rates and ameliorating quality of life.
Section snippets
Features of neuroendocrine differentiation in prostate cancer
NED is a common feature of prostatic adenocarcinomas. Pure neuroendocrine prostate cancer (NEPC) and a small cell PC represent rare and aggressive tumors, such as primary carcinoids, which are also very rare, but usually not aggressive. In most cancers, the NE component coexists with non-NE component, displaying a variable extension of the two components, potentially ranging from 1 to 99%. NE component usually occupies less than 5% of the overall tumor mass and, in general, in NEPC NE component
Pathogenetic mechanisms involved in neuroendocrine differentiation and progression in prostate cancer
NE cells of the prostate are widely distributed in normal prostatic acini and ducts. The origin of NE cells in PC is controversial. It is suggested that NEPC cells have the same origin as normal NE cells from neural crest and are differentiated from common pluripotent stem cells (as reported in the following paragraph). In fact, NE cells have some features of cancer stem cells (CSCs), such as the expression of CD44 and CD133, which may give resistance to hormonal therapy and lead to tumor
Cancer stem cells and neuroendocrine differentiation in prostate cancer
Cancer stem cells (CSC) consist of a minor subpopulation of tumor cells (typically less than 1–2%) possessing the ability to self-renew and recreate the entire tumor, inclusive of all cell types [41]. In PC, CSC are typically quiescent, resistant to traditional therapies that depend on continuous cell cycle activity, such as chemotherapy and radiotherapy, and do not express the luminal differentiation markers AR and PSA, while they express stemness markers, including β1 integrins, CD133, CD44,
Epithelial-to-mesenchymal transition and neuroendocrine differentiation in prostate cancer
Epithelial-to-mesenchymal transition (EMT) is characterized by the loss of epithelial differentiation and by acquisition of mesenchymal phenotype with increased cell motility and invasion. EMT is considered to be a normal physiologic process, but it is also implicated in the progression of early stage tumors into invasive malignancies and it is often associated with tumor recurrence [50]. Many stimuli in the tumor microenvironment, such as hypoxia and growth factors (e.g. TGF-β, FGF and IGF-1),
Current diagnostic procedures on neuroendocrine differentiation of prostate cancer
The diagnosis of NEPC is not straightforward and immediate; it can, therefore, sometimes be misdiagnosed. Low serum PSA value and clinical history can help clinicians but confirmation by way of tissue biopsy is often required. The measurement of serum NE markers and IHC positivity for NE markers support the diagnosis.
CgA is considered as a main specific NE tumor marker. It belongs to the secretogranin family and CgA plasmatic levels could reflect the NE activity present in different organs,
Prognostic and predictive significance of neuroendocrine differentiation in prostatic carcinoma
Just as NE cells are present in all stages of PC, NED can also be identified in different stages of PC with a corresponding prognostic impact. However, the prognostic significance of NED in hormone naive prostate cancers and after radical prostatectomy is controversial [73], [76], but only in CRPC NED could be associated with a poor prognosis [77], [78]. In addition, for Gleason 8–10 PC, the presence of NED even only more than 1% is associated with poor clinical outcome for CRPC patients
Chemotherapy
In the past, some phase II trials of PC patients with NED have evaluated, at various tumor stages, the efficacy of single drug, as oral estramustine [85], or the combination of different cytotoxic drugs, for example, the association of cisplatin, etoposide and doxorubicin [86] or the association of cisplatin and docetaxel [87], with disappointing results. Subsequently, other studies have looked into the association of carboplatin and etoposide on the basis of results obtained with the same
Conclusions
The exact pathogenesis of NED in the prostate tumor is still little known, although multiple pathways are involved. However, it has now been confirmed that PC patients treated with ADT, particularly those with advanced stage but lower serum PSA levels, should be evaluated for the presence of NED, which may represent one of the key mechanisms of CRPC. With the introduction of new highly potent AR-targeted agents into the clinic (i.e., abiraterone acetate, MDV3100, TAK700), ADT-related NEPC is
Conflict of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
Reviewers
Dr. Michal Mego, MD, PhD, National Cancer Institute, Department of Medical Oncology, Klenova 1, Bratislava, Slovakia.
Dr. Dominik R. Berthold, Medical Oncology, Rue Bugnon 46, CH-1011 Lausanne, Switzerland.
Vincenza Conteduca, M.D., graduated from the University of Bari, Italy and received her title of specialist in Oncology at the Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, Italy. Now she is working at Department of Medical Oncology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola (FC), Italy and she is attending a Ph.D. in clinical and experimental oncology at the University of Foggia. Her main research
References (108)
- et al.
Influence neuroendocrine tumor cells on proliferation in prostatic carcinoma
Hum Pathol
(2005) - et al.
Parathyroid hormone-related protein is expressed by prostatic neuroendocrine cells
Urology
(1994) - et al.
Siah2-dependent concerted activity of HIF & FoxA2 regulates formation of neuroendocrine phenotype & neuroendocrine prostate tumors
Cancer Cell
(2010) - et al.
Human ASH1 expression in prostate cancer with neuroendocrine differentiation
Mod Pathol
(2008) - et al.
Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment
Urology
(1998) - et al.
Differential expression of interleukin-8 and its receptors in the neuroendocrine and non neuroendocrine compartments of prostatencancer
Am J Pathol
(2005) - et al.
Epithelial immune cell-like transition (EIT): a proposed transdifferentiation process underlying immune-suppressive activity of epithelial cancers
Differentiation
(2012) - et al.
Prostate cancer stem cells
Clin Genitourin Cancer
(2012) - et al.
Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells
J Urol
(2010) - et al.
The epithelial-mesenchymal transition generates cells with properties of stem cells
Cell
(2008)
Circulating tumor cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data
Lancet Oncol
expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease
J Urol
Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in cancer and leukemia Group B 9480 study
Urology
Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers
J Urol
Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features
Ann Oncol
Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial
Ann Oncol
Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study
Urology
Somatostatin analogues and estrogens in the treatment of androgen ablation refractory prostate adenocarcinoma
J Urol
Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin a in patients with androgen ablation refractory prostate cancer
J Urol
Pasireotide (SOM230): development, mechanism of action and potential applications
Mol Cell Endocrinol
Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling
Eur J Cancer
Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments
Ann Oncol
The grey zone between pure (neuro)endocrine and non-(neuro)endocrine tumors: a comment on concepts and classification of mixed exocrine-endocrine neoplasms
Virchows Arch
Immunohistochemical characterization of neuroendocrine cells in prostate cancer
Prostate
Bcl2 protooncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell
Arch Pathol Lab Med
Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway
Endocr Relat Cancer
Neuroendocrine differentiation in prostate cancer
Am J Transl Res
Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer
Prostate
CD133, a novel marker for human prostatic epithelial stem cells
J Cell Sci
Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells
Endocr Relat Cancer
Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines
Prostate
Clinical implications of neuroendocrine differentiation in prostate cancer
Prostate Cancer Prostatic Dis
Molecular Characterization of neuroendocrine prostate cancer and identification of new drug targets
Cancer Discov
Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer
Neoplasia
Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting
Clin Cancer Res
Neuroendocrine tumor cells in prostate cancer: evaluation of the neurosecretory products serotonin, bombesin, and gastrin-impact on angiogenesis and clinical follow-up
Prostate
Epidermal growth factor-induced neuroendocrine differentiation and apoptotic resistance of androgen-independent human prostate cancer cells
Endocr Relat Cancer
Human ASH-1 promotes neuroendocrine differentiation in androgen deprivation conditions and interferes with androgen responsiveness in prostate cancer cells
Prostate
Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation
Cancer Res
Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation
Prostate
Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment
Prostate
STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells
Prostate
Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK
Oncogene
Interleukin-1β promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features
Cancer Res
Phosphatidylinositol 3-Kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer
J Biol Chem
Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells
Mol Cancer
Androgen depletion induces senescence in prostate cancer cells through down-regulation of Skp2
Neoplasia
Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status
Ann Oncol
Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic and neoplastic human prostate
Prostate
Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells
Endocr Relat Cancer
Cited by (73)
Blocking GRP/GRP-R signaling decreases expression of androgen receptor splice variants and inhibits tumor growth in castration-resistant prostate cancer
2021, Translational OncologyCitation Excerpt :Most recently, Aggarwal and colleagues have reported that prostatic metastatic bone cancer is made up of about 10–15% NEPC (small cell carcinoma) which is histologically similar to NE prostate cancer (NEPC) metastasis to the lung and liver [17]. Regardless NEPC develops from primary NE cells or prostatic adenocarcinoma cells that transdifferentiate to therapy-induced NEPC (tNEPC), the tumors express NE markers [11,18,19], NEPC/NED has a more aggressive clinical behavior, an unfavorable prognosis, and is a non-curable disease [20]. Therefore, developing a new treatment for CRPC and NEPC/NED is a critical challenge.
The Landscape of Circular RNA in Cancer
2019, CellPRMT5 promotes chemotherapy-induced neuroendocrine differentiation in NSCLC
2023, Thoracic CancerAutonomous action and cooperativity between the ONECUT2 transcription factor and its 3′ untranslated region
2023, Frontiers in Cell and Developmental Biology
Vincenza Conteduca, M.D., graduated from the University of Bari, Italy and received her title of specialist in Oncology at the Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, Italy. Now she is working at Department of Medical Oncology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola (FC), Italy and she is attending a Ph.D. in clinical and experimental oncology at the University of Foggia. Her main research interests focus on the diagnosis and treatment of solid tumors. She is co-author of some full papers, books and abstracts presented at national and international meetings.